drugset

drugset / Trial / NCT00781976

Antiviral Activity of AZD7295 in HCV Carriers

NCT00781976 ↗

Phase 1 Completed 31 enrolled Arrow Therapeutics

RandomizedParallel-groupQuadruple-blindTreatment

Summary

PK, safety study of AZD7295 in HCV carriers

Timeline

Start: 2008-11
Primary completion: 2010-03
Completion: 2010-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	AZD7295	Small molecule	700 mg	Oral

Indications